StockData
NAIINasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends June 30

NATURAL ALTERNATIVES INTERNATIONAL INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 28, 2026
$1.15+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$6.98M
P/E (TTM)
–
Dividend yield
–

About Natural Alternatives International

Medicinal Chemicals & Botanical Products, SIC 2833

Natural Alternatives International, Inc. formulates, manufactures, and markets nutritional supplements, operating through two segments: private-label contract manufacturing and patent and trademark licensing. As its primary business activity, the company provides contract manufacturing services to businesses that distribute vitamins, minerals, herbal supplements, and health care items to consumers. Its product formats include tablets, capsules, powders, and chewable wafers, supported by services such as custom formulation, clinical study design, packaging, and regulatory assistance. It also commercializes a patent estate centered on the raw material beta-alanine under brands including CarnoSyn, SR CarnoSyn, CarnoSyn 4X, and TriBsyn through raw material sales and licensing agreements.

The company maintains corporate headquarters in Carlsbad, California, alongside a dedicated powder blending and packaging facility, with another manufacturing facility situated in nearby Vista, California. Internationally, its European subsidiary operates an analytical laboratory, manufacturing, packaging, and distribution facility in Manno, Switzerland. Its contract manufactured goods reach consumers across the United States and international markets, primarily Europe and Asia, as well as Australia, Mexico, and Canada.

Summary of the business section of Natural Alternatives International's latest annual report, written by StockData.

Company profile

Company

Legal name
NATURAL ALTERNATIVES INTERNATIONAL INC
Founded
1980
Headquarters
Carlsbad, CA
Address
1535 Faraday Avenue 92008-7319
Phone
(760) 736-7700
Employees
219, Jun 30, 2026
Industry
Medicinal Chemicals & Botanical Products
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
HASKELL & WHITE LLP, Irvine, California

Stock & identifiers

Ticker
NAII
Exchange
Nasdaq
IPO date
Oct 28, 1993
Shares outstanding
22M, Sep 28, 2026
Public float
$6.26M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
787253
CUSIP
638842302
ISIN
US6388423021
LEI
549300QOT5V1NZ8WZY48
EIN
84-1007839

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark A. LedouxCEO/Chairman, Director743,558
Kenneth WolfPresident, COO, & Sec.126,831
Michael E. FortinChief Financial Officer58,739
Alan G. DunnDirector99,211
Laura Kay MatherlyDirector42,000
Guru RamanathanDirector38,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$562.52K$494.46K$382.00K$-46–
FY2024$794.01K$760.41K$529.21K$-16–
FY2023$915.15K$832.28K$571.94K$-31–
FY2022$954.27K$828.15K$589.59K$-38–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we employed 219 employees in the U.S., 46 who were employed in research, laboratory and quality control, 10 in sales and marketing, and 162 in manufacturing and administration.”

Corporate history

Events identified from SEC filings